SAR405: Selective ATP-Competitive Vps34 Inhibitor for Autophagy and Vesicle Trafficking Modulation

Executive Summary: SAR405 is a nanomolar-potency, highly selective ATP-competitive inhibitor of Vps34, the class III phosphoinositide 3-kinase essential for autophagy and vesicle trafficking (APExBIO). It exhibits a Kd of 1.5 nM and an IC₅₀ of 1 nM against human recombinant Vps34, with no significant inhibition of class I/II PI3Ks or mTOR up to 10 μM (Park et al., 2023). SAR405 impairs late endosome-lysosome function and autophagosome formation, making it a precise tool for mechanistic studies. Its selectivity supports studies on the Vps34-ULK1-AMPK axis, crucial for understanding autophagy regulation under cellular energy stress. Storage and solubility parameters ensure experimental reproducibility in advanced cell biology workflows.

Biological Rationale

Vps34 is the sole class III PI3K isoform in eukaryotic cells. It generates phosphatidylinositol 3-phosphate (PI3P), a lipid essential for membrane trafficking and autophagy initiation. Autophagy is a conserved process for degradation and recycling of cytoplasmic components, particularly important during energy stress and nutrient deprivation (Park et al., 2023). Recent work has clarified that autophagy requires a minimum energetic threshold and is tightly regulated by upstream kinases, notably AMPK, ULK1, and mTORC1. Vps34 integrates signals from these pathways to orchestrate autophagosome biogenesis and vesicle maturation (SAR405: Precision Dissection of Vps34 Pathways).

Mechanism of Action of SAR405

SAR405 is a highly potent ATP-competitive inhibitor targeting the Vps34 kinase active site. With a dissociation constant (Kd) of 1.5 nM and an IC₅₀ of 1 nM, it binds selectively to Vps34 without affecting class I/II PI3Ks or mTOR at concentrations up to 10 μM (APExBIO). Structural studies reveal that SAR405 occupies the ATP-binding cleft, locking Vps34 in an inactive conformation. This blockade impairs PI3P synthesis, disrupting downstream vesicle trafficking and autophagosome nucleation. In cellular models such as GFP-LC3 HeLa and H1299, SAR405 prevents autophagosome formation and leads to the accumulation of swollen late endosome-lysosomes and defective cathepsin D maturation. These effects are synergistic with mTOR inhibitors like everolimus, allowing for combined pathway dissection (Redefining Vps34 Inhibition).

Evidence & Benchmarks

• SAR405 exhibits a Kd of 1.5 nM and IC₅₀ of 1 nM for human recombinant Vps34 under standard kinase assay conditions (25°C, pH 7.4) (APExBIO).
• Does not inhibit class I or II PI3K isoforms or mTOR at concentrations up to 10 μM, demonstrating exceptional selectivity (Park et al., 2023).
• Prevents autophagosome formation in GFP-LC3 HeLa and H1299 cell lines within 2–4 hours of treatment (1 μM) (Targeted Autophagy Inhibition).
• Induces accumulation of swollen late endosome-lysosomes and impairs cathepsin D maturation, confirming disruption of vesicle trafficking (Park et al., 2023).
• Synergizes with mTOR inhibitors (e.g., everolimus) to enhance autophagy inhibition and dissect pathway interactions (Precision Vps34 Inhibition).

Applications, Limits & Misconceptions

SAR405 is widely applied in cancer, neurodegenerative disease, and fundamental cell biology research to dissect Vps34 kinase signaling and autophagy regulation. Its high selectivity and nanomolar potency enable precise mechanistic studies, especially in cellular models where class I/II PI3K or mTOR inhibition would confound results. SAR405 is instrumental in mapping the pathway architecture between Vps34, ULK1, and AMPK during cellular energy stress (Park et al., 2023).

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I/II PI3Ks or mTOR—it is not a pan-PI3K inhibitor and cannot substitute for broader PI3K or mTOR blockade.
• Autophagy inhibition by SAR405 requires functional Vps34; its effects are absent in Vps34 knockout models.
• SAR405 is not water-soluble—it must be dissolved in DMSO (>10 mM) or ethanol (with ultrasonic assistance) for experimental use.
• SAR405 does not induce autophagy; it blocks autophagosome formation and vesicle maturation.
• Long-term storage of diluted solutions is not recommended; the compound should be aliquoted and stored at <–20°C as concentrated stock.

This article extends previous summaries such as SAR405: Selective ATP-Competitive Vps34 Inhibitor for Targeted Modulation by providing updated insights from the 2023 AMPK-ULK1 paradigm shift, clarifying how SAR405 enables dissection of non-canonical autophagy regulation. Additionally, it expands on SAR405: Precision Dissection of Vps34 Pathways by presenting evidence benchmarks and workflow integration parameters for reproducible research.

Workflow Integration & Parameters

SAR405 (A8883, APExBIO) is provided as a dry powder and should be reconstituted in DMSO (>10 mM) or ethanol (with ultrasonic assistance). Solutions should be aliquoted and stored at –20°C for several months; avoid repeated freeze-thaw cycles and long-term storage of diluted solutions. In cellular assays, concentrations between 100 nM and 2 μM are effective for acute Vps34 inhibition. Autophagy flux can be monitored by LC3-II accumulation and p62/SQSTM1 turnover. For synergy studies with mTOR inhibitors, sequential or combined treatments can clarify pathway cross-talk. SAR405 is unsuitable for in vivo applications unless pharmacokinetic and toxicity profiles are established. Detailed protocols are available on the APExBIO SAR405 product page.

Conclusion & Outlook

SAR405 is a gold-standard tool compound for dissecting Vps34 kinase biology, autophagy inhibition, and vesicle trafficking modulation. Its exceptional selectivity and nanomolar potency allow researchers to precisely interrogate the Vps34-ULK1-AMPK axis, especially in contexts of cancer and neurodegenerative disease. APExBIO’s SAR405 supports reproducible, robust, and mechanistically informative experiments. Future research will benefit from SAR405’s ability to clarify pathway interactions and refine our understanding of autophagy regulation in health and disease. For further reading, see SAR405 and the New Paradigm of Vps34 Inhibition in Autophagy, which provides a comprehensive overview of SAR405’s role in light of recent AMPK-ULK1 discoveries.